|
EP0969865B1
(en)
*
|
1996-05-23 |
2006-12-06 |
The Scripps Research Institute |
Mhc class ii antigen-presenting systems and methods for activating cd4?+ t cells
|
|
US6291430B1
(en)
*
|
1997-09-12 |
2001-09-18 |
Ludwig Institute For Cancer Research |
Mage-3 peptides presented by HLA class II molecules
|
|
US6576428B1
(en)
|
1998-05-11 |
2003-06-10 |
Miltenyi Biotech Gmbh |
Direct selection of antigen-specific T cells, compositions obtained thereby and methods of use thereof
|
|
US6230662B1
(en)
|
1998-06-22 |
2001-05-15 |
Theresa Miale |
Animal lift and transport apparatus and method for using the same
|
|
AU5474399A
(en)
*
|
1998-08-10 |
2000-03-06 |
Chiron Corporation |
Engineered antigen-presenting cells expressing an array of antigens and uses thereof
|
|
US7807377B2
(en)
|
1998-10-20 |
2010-10-05 |
Salvatore Albani |
Method of isolating antigen-specific T cells employing artificial antigen presenting cells
|
|
DE69942100D1
(de)
*
|
1998-10-20 |
2010-04-15 |
Androclus Technologies S R L I |
Künstliche antigen-spezifischen zellen und zugehörige verfahren
|
|
US6225443B1
(en)
*
|
1999-05-19 |
2001-05-01 |
Wisconsin Alumni Research Foundation |
Cytotoxic T lymphocyte epitopes of the major outer membrane protein of chlamydia trachomatis
|
|
US7521202B2
(en)
|
1999-12-17 |
2009-04-21 |
The Board Of Regents Of The University Of Oklahoma |
Method and apparatus for the production of soluble MHC antigens and uses thereof
|
|
DE10009341A1
(de)
*
|
2000-02-22 |
2001-09-06 |
Florian Kern |
Verfahren zur antigen-spezifischen Stimulation von T-Lymphozyten
|
|
US7541184B2
(en)
|
2000-02-24 |
2009-06-02 |
Invitrogen Corporation |
Activation and expansion of cells
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
WO2001080833A1
(en)
*
|
2000-04-20 |
2001-11-01 |
Salvatore Albani |
Methods for isolation, quantification, characterization and modulation of antigen-specific t cells
|
|
EP1362058B1
(en)
|
2000-10-10 |
2009-06-03 |
The Board of Regents of The University of Oklahoma |
Comparative ligand mapping from mhc positive cells
|
|
US20070026433A1
(en)
|
2001-03-09 |
2007-02-01 |
Hildebrand William H |
Epitope testing using soluble HLA
|
|
WO2002056908A2
(en)
*
|
2001-01-16 |
2002-07-25 |
Hildebrand William H |
Artificial antigen-presenting cells
|
|
US7579007B2
(en)
*
|
2001-02-13 |
2009-08-25 |
Jdm Technologies, Inc. |
Production of “biological carriers” for induction of immune responses and inhibition of viral replication
|
|
US20040071671A1
(en)
*
|
2001-02-20 |
2004-04-15 |
Leturcq Didier J. |
Cell therapy method for the treatment of tumors
|
|
PT1377251E
(pt)
*
|
2001-02-20 |
2008-08-05 |
Ortho Mcneil Janssen Pharm |
Método de terapia celular para o tratamento de tumores
|
|
FR2824567B1
(fr)
*
|
2001-05-11 |
2003-08-08 |
Inst Nat Sante Rech Med |
Procede d'obtention de lymphocytes tr1 regulateurs specifiques d'antigene
|
|
US7745140B2
(en)
*
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
US7670781B2
(en)
*
|
2002-01-03 |
2010-03-02 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an agent that provides a primary activation signal and another agent that provides a co-stimulatory signal
|
|
US7638326B2
(en)
|
2002-01-03 |
2009-12-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform
|
|
ATE353954T1
(de)
|
2002-10-11 |
2007-03-15 |
Sentoclone Therapeutics Ab |
Immuntherapie für krebs
|
|
US20040072262A1
(en)
*
|
2002-10-11 |
2004-04-15 |
Montero-Julian Felix A. |
Methods and systems for detecting MHC class I binding peptides
|
|
US7435592B2
(en)
|
2003-05-13 |
2008-10-14 |
Immunovative Therapies, Ltd. |
Compositions for allogeneic cell therapy
|
|
EP1692504A4
(en)
*
|
2003-11-03 |
2007-06-27 |
Beckman Coulter Inc |
METHODS BASED ON DETECTION SOLUTIONS OF PEPTIDES FIXING AT THE MHC
|
|
US7592431B2
(en)
|
2004-02-26 |
2009-09-22 |
Immunovative Therapies, Ltd. |
Biodegradable T-cell Activation device
|
|
PT2573166T
(pt)
|
2004-02-26 |
2016-07-07 |
Immunovative Therapies Ltd |
Métodos para preparar células-t para terapia celular
|
|
WO2005111624A2
(en)
*
|
2004-05-07 |
2005-11-24 |
Beckman Coulter, Inc. |
Mhc bridging system for detecting ctl-mediated lysis of antigen presenting cells
|
|
CA2568344C
(en)
|
2004-05-27 |
2016-01-19 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
US7678379B2
(en)
*
|
2004-06-17 |
2010-03-16 |
Beckman Coulter, Inc. |
Mycobacterium tuberculosis epitopes and methods of use thereof
|
|
EP1712615A1
(en)
*
|
2005-04-15 |
2006-10-18 |
Txcell |
In vitro production of a cell population using feeder cells
|
|
PL2397156T3
(pl)
|
2005-06-08 |
2017-07-31 |
Dana-Farber Cancer Institute, Inc. |
Sposoby i kompozycje do leczenia uporczywych infekcji i nowotworu poprzez hamowanie ścieżki zaprogramowanej śmierci komórki 1 (PD-1)
|
|
WO2006138449A2
(en)
*
|
2005-06-16 |
2006-12-28 |
The Wistar Institute |
Method for identifying a mhc class ii-dependent tumor-associated t helper cell antigen
|
|
WO2007071410A1
(en)
|
2005-12-21 |
2007-06-28 |
Sentoclone Ab |
Method for treating urinary bladder cancer
|
|
AU2006328943B2
(en)
|
2005-12-21 |
2011-07-21 |
Sentoclone International Ab |
Improved method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer
|
|
AU2006328944B2
(en)
|
2005-12-21 |
2011-08-25 |
Sentoclone International Ab |
Method for treating disseminated cancer
|
|
AU2006328945B2
(en)
|
2005-12-21 |
2011-06-30 |
Sentoclone International Ab |
Method for treating malignant melanoma
|
|
MX2008011302A
(es)
|
2006-03-01 |
2008-11-04 |
Janssen Pharmaceutica Nv |
Tratamiento de cancer que combina agente de linfodeplecion con linfocitos t citotoxicos y citocinas.
|
|
KR20090060450A
(ko)
*
|
2006-10-04 |
2009-06-12 |
얀센 파마슈티카 엔.브이. |
불활성화 인공 항원 제시 세포의 제조 및 세포 치료법에서 이들의 용도
|
|
WO2008083174A2
(en)
*
|
2006-12-27 |
2008-07-10 |
Emory University |
Compositions and methods for the treatment of infections and tumors
|
|
US20120034155A1
(en)
*
|
2010-08-03 |
2012-02-09 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Artificial cells
|
|
CN102282265B
(zh)
|
2008-11-28 |
2020-07-24 |
埃默里大学 |
用于治疗传染病和肿瘤的方法
|
|
US8075895B2
(en)
|
2009-09-22 |
2011-12-13 |
Janssen Pharmaceutica N.V. |
Identification of antigenic peptides from multiple myeloma cells
|
|
EP2404618A1
(en)
|
2010-07-07 |
2012-01-11 |
Stichting Katholieke Universiteit meer in het bijzonder Radboud Universiteit Nijmegen |
Immunomodulatory protein constructs with a helical polymeric backbone.
|
|
WO2012017678A1
(ja)
*
|
2010-08-06 |
2012-02-09 |
株式会社ケーナインラボ |
免疫機能の強化剤
|
|
JP5934783B2
(ja)
|
2011-05-03 |
2016-06-15 |
イミュノバティブ セラピーズ，リミテッド |
生細胞を含む生物学的薬剤の取り扱い方法
|
|
CA2838046C
(en)
|
2011-05-03 |
2023-03-07 |
Immunovative Therapies, Ltd. |
Induction of il-12 using immunotherapy
|
|
WO2013163171A1
(en)
|
2012-04-24 |
2013-10-31 |
Kaufman Dan S |
Method for developing natural killer cells from stem cells
|
|
CN112795594B
(zh)
|
2013-05-14 |
2025-09-19 |
得克萨斯州大学系统董事会 |
工程化嵌合抗原受体(car)t细胞的人应用
|
|
EP3967325A1
(en)
*
|
2013-12-16 |
2022-03-16 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon
|
|
JP6640726B2
(ja)
|
2014-02-14 |
2020-02-05 |
ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム |
キメラ抗原受容体及びその製造方法
|
|
WO2015148960A1
(en)
|
2014-03-28 |
2015-10-01 |
The Board Of Regents Of The University Of Oklahoma |
Compositions comprising soluble hla/m. tuberculosis-specific ligand complexes and methods of production and use thereof
|
|
CN106459924A
(zh)
|
2014-04-23 |
2017-02-22 |
得克萨斯州大学系统董事会 |
用于疗法中的嵌合抗原受体(car)及其制备方法
|
|
US20170044500A1
(en)
|
2014-04-24 |
2017-02-16 |
Board Of Regents, The University Of Texas System |
Application of induced pluripotent stem cells to generate adoptive cell therapy products
|
|
CA2964783C
(en)
|
2014-11-05 |
2024-01-23 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (car) to selectively target protein complexes
|
|
EP3536707A1
(en)
|
2014-11-05 |
2019-09-11 |
Board of Regents, The University of Texas System |
Gene modified immune effector cells and engineered cells for expansion of immune effector cells
|
|
FR3031519B1
(fr)
|
2015-01-14 |
2016-12-30 |
Arkema France |
Composition a base de terpolymere electroactif
|
|
DK3271382T3
(da)
*
|
2015-03-16 |
2020-05-04 |
Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft |
Fremgangsmåde til detektion af nye immunogene T-celleepitoper og isolering af nye antigenspecifikke T-cellereceptorer ved hjælp af et MHC-cellebibliotek
|
|
WO2017075147A1
(en)
|
2015-10-27 |
2017-05-04 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor molecules and uses thereof
|
|
WO2017214333A1
(en)
|
2016-06-08 |
2017-12-14 |
Intrexon Corporation |
Cd33 specific chimeric antigen receptors
|
|
WO2018023100A2
(en)
|
2016-07-29 |
2018-02-01 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies and related methods
|
|
WO2018089423A1
(en)
|
2016-11-09 |
2018-05-17 |
Musc Foundation For Research Development |
Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy
|
|
WO2018132494A1
(en)
|
2017-01-10 |
2018-07-19 |
Intrexon Corporation |
Modulating expression of polypeptides via new gene switch expression systems
|
|
US11285196B2
(en)
|
2017-03-13 |
2022-03-29 |
Eslam Abbas Baseuny |
Multivalent biologic constructs for inducing a therapeutic modulation of cellular response and uses thereof
|
|
BR112019021745A2
(pt)
|
2017-04-18 |
2020-05-05 |
Fujifilm Cellular Dynamics Inc |
células efetoras imunológicas antígeno-específicas
|
|
IL270990B2
(en)
|
2017-06-07 |
2024-02-01 |
Precigen Inc |
Expression of new cell markers
|
|
US12178787B2
(en)
|
2017-10-12 |
2024-12-31 |
Board Of Regents, The University Of Texas System |
T cell receptors for immunotherapy
|
|
JP7273421B2
(ja)
|
2018-02-21 |
2023-05-15 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
ナチュラルキラー細胞の活性化および拡大のための方法ならびにその使用
|
|
MX2021006208A
(es)
|
2018-11-28 |
2021-10-01 |
Univ Texas |
Edición por multiplexación del genoma de células inmunitarias para mejorar la funcionalidad y resistencia al entorno supresor.
|
|
WO2020112493A1
(en)
|
2018-11-29 |
2020-06-04 |
Board Of Regents, The University Of Texas System |
Methods for ex vivo expansion of natural killer cells and use thereof
|
|
CN120605327A
(zh)
|
2019-11-06 |
2025-09-09 |
贝勒医学院 |
用于产生细胞毒性效应子记忆t细胞以用于癌症的t细胞治疗的方法
|
|
WO2021163191A1
(en)
|
2020-02-10 |
2021-08-19 |
Board Of Regents, The University Of Texas System |
Methods for rapid cloning and expression of hla class i cells
|
|
CA3179599A1
(en)
|
2020-05-27 |
2021-12-02 |
Marco ALESSANDRINI |
Adapter molecules to re-direct car t cells to an antigen of interest
|
|
US12275766B2
(en)
|
2020-12-23 |
2025-04-15 |
Janssen Biotech, Inc. |
Neoantigen peptide mimics
|
|
US20250235478A1
(en)
|
2022-04-28 |
2025-07-24 |
Musc Foundation For Research Development |
Chimeric antigen receptor modified regulatory t cells for treating cancer
|